LV12188B - 1,4-dihidro-1,4-diokso-1h-naftalīna triciklisku atvasinājumu pielietojums jaunu savienojumu iegūšanai un to izmantošana terapijā - Google Patents

1,4-dihidro-1,4-diokso-1h-naftalīna triciklisku atvasinājumu pielietojums jaunu savienojumu iegūšanai un to izmantošana terapijā Download PDF

Info

Publication number
LV12188B
LV12188B LVP-98-136A LV980136A LV12188B LV 12188 B LV12188 B LV 12188B LV 980136 A LV980136 A LV 980136A LV 12188 B LV12188 B LV 12188B
Authority
LV
Latvia
Prior art keywords
dihydro
dioxo
thiazole
naphtho
new product
Prior art date
Application number
LVP-98-136A
Other languages
English (en)
Other versions
LV12188A (lv
Inventor
Odile Boutherin-Falson
Stephanie Desquand-Billiald
Anita Favrou
Michel Finet
Olivier Tembo
Jean-Luc Torregrosa
Sylvie Yannic-Arnoult
Florence Domagala-Le Marguer
Original Assignee
Laboratoire Innothera
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoire Innothera filed Critical Laboratoire Innothera
Publication of LV12188A publication Critical patent/LV12188A/lv
Publication of LV12188B publication Critical patent/LV12188B/lv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/24—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones the carbon skeleton containing carbon atoms of quinone rings
    • C07C225/26—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones the carbon skeleton containing carbon atoms of quinone rings having amino groups bound to carbon atoms of quinone rings or of condensed ring systems containing quinone rings
    • C07C225/30—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones the carbon skeleton containing carbon atoms of quinone rings having amino groups bound to carbon atoms of quinone rings or of condensed ring systems containing quinone rings of condensed quinone ring systems formed by two rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C46/00—Preparation of quinones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C50/00—Quinones
    • C07C50/24—Quinones containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C50/00—Quinones
    • C07C50/26—Quinones containing groups having oxygen atoms singly bound to carbon atoms
    • C07C50/32—Quinones containing groups having oxygen atoms singly bound to carbon atoms the quinoid structure being part of a condensed ring system having two rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/60—Naphthoxazoles; Hydrogenated naphthoxazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/84—Naphthothiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/12—One of the condensed rings being a six-membered aromatic ring the other ring being at least seven-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Claims (6)

  1. LV 12188 IZGUDROJUMA FORMULA 1. Triciklisku atvasinājumu un to farmaceitiski pieņemamu sāļu ar vispārējo formulu (I) o
    c kur A ir sēra vai skābekļa atoms; R3N-grupa, kur R3 ir ūdeņraža atoms, CV C5alkilgrupa; aizvietots vai neaizvietots aromātisks gredzens; vai aizvietots vai neaizvietots heteroaromātisks gredzens; Rļ ir CrC5alkilgrupa vai R4NH-grupa, kur R4 ir ūdeņraža atoms; C,-C5alkilgrupa; aizvietots vai neaizvietots aromātisks gredzens; aizvietots vai neaizvietots heteroaromātisks gredzens; aromātisks gredzens, kas var būt aizvietots vai neaizvietots ar vienu vai vairākām akceptora vai donora grupām; vai heteroaromātisks gredzens ar vienu vai vairākiem heteroatomiem, kas var būt aizvietots vai neaizvietots ar akceptora vai donora grupām; R2 ir ūdeņraža vai halogēna atoms, Cļ-Csalkilgrupa; skābekļa atoms, kas var būt aizvietots vai neaizvietots ar C^Csalkilgrupu; vai NR5R5.-grupa, kur R5 un R5· neatkarīgi viena no otras ir ūdeņraža vai skābekļa atoms vai vienvērtīga C,-C5 organiska grupa; pielietojums ārstniecisku preparātu iegūšanā, kas paredzēti slimību, kas saistītas ar venozo funkciju maiņu un/vai iekaisuma tūskas ārstēšanai. 2. 4,9-Dihidro-4,9-diokso-1,2-dimetil-1 H-nafto[2,3-d][sic2,3-d-agrākais]imidazola sulfāts kā jauns produkts. 3. 4,9-Dihidro-4,9-diokso-2-(2-fluorfenil)-1 H-nafto[2,3-d]imidazols kā jauns produkts. 4. 4,9-Dihidro-4,9-diokso-2-(2-fluorfenil)-nafto[2,3-d]oksazols kā jauns produkts. 2 5. 4,9-Dihidro-4,9-diokso-2-(3-fluorfenil)- nafto[2,3-d]oksazols kā jauns produkts. 6. 4,9-Dihidro-4,9-diokso-2-(4-fluorfenil)- nafto[2,3-d]oksazols kā jauns produkts. 7. 4,9-Dihidro-4,9-diokso-2-(2-metilfenil)- nafto[2,3-d]oksazols kā jauns produkts. 8. 4,9-Dihidro-4,9-diokso-2-(3-metilfenil)- nafto[2,3-d]oksazols kā jauns produkts. 9. 4,9-Dihidro-4,9-diokso-2-(4-metilfenil)-nafto[2,3-d]oksazols kā jauns produkts. 10. 2-(2-Hlorfenil)-4,9-dihidro-4,9-diokso-nafto[2,3-d]oksazols kā jauns produkts. 11.2-(4-Hlorfenil)-4,9-dihidro-4,9-diokso-nafto[2,3-d]oksazols kā jauns produkts. 12. 4,9-Dihidro-4,9-diokso-2-(2-tienil)- nafto[2,3-d]oksazols kā jauns produkts. 13. 4,9-Dihidro-4,9-diokso-2-(2-fluorfenil)-nafto[2,3-d]tiazols kā jauns produkts. 14. 4,9-Dihidro-4,9-diokso-2-(3-fluorfenil)-nafto[2I3-d]tiazols kā jauns produkts. 15. 4,9-Dihidro-4,9-diokso-2-(4-fluorfenil)-nafto[2,3-d]tiazols kā jauns produkts. 16. 2-(2,4-Difluorfenil)-4,9-dihidro-4,9-diokso-nafto[2,3-d]tiazols kā jauns produkts. 17. 4,9-Dihidro-4,9-diokso-2-(3-piridil)-nafto[213-d]tiazols kā jauns produkts. 18. 4,9-Dihidro-4,9-diokso-2-(4-piridil)-nafto[2,3-d]tiazola sulfāts kā jauns produkts 19. 4,9-Dihidro-4,9-diokso-2-(3-furil)nafto[213-d]tiazols kā jauns produkts. 20. 2-(5-Hlorfuran-2-ii)-4,9-dihidro-4,9-diokso-nafto[2,3-d]tiazola sulfāts kā jauns produkts. 3 LV 12188 21.4,9*Dihidro-419-diokso-2-(2-tienil)-nafto[213-d]tiazo!s kā jauns produkts. 22. 4,9-Dihidro-4,9-diokso-2-(3-tienil)-nafto[2,3-d]tiazols kā jauns produkts. 23. 4,9-Dihidro-4,9-diokso-2-fenilamino-nafto[2,3-d]tiazols kā jauns produkts. 24. 4,9-Dihidro-4,9-diokso-8-metoksi-2-fenilnafto[2,3-d]tiazols kā jauns produkts. 25. 4,9-Dihidro-4,9-diokso-5-metoksi-2-fenilnafto[2,3-d]tiazols kā jauns produkts. 26. 4,9-Dihidro-4,9-diokso-7-metoksi-2-fenilnafto[2,3-d]tiazols kā jauns produkts. 27. 4,9-Dihidro-4,9-diokso-6-metoksi-2-fenilnafto[2,3-d]tiazols kā jauns produkts. 28. 4,9-Dihidro-4,9-diokso-8-oksi-2-fenilnafto[2,3-d]tiazols kā jauns produkts. 29. 4,9-Dihidro-4,9-diokso-2-(1-pirolil)-nafto[2,3-d]tiazols kā jauns produkts. 30. 2-(5-Bromfuran-2-il)-4,9-dihidro-4,9-diokso-nafto[2)3-d]tiazols kā jauns produkts. 31.2-(4,5-Dibromfuran-2-il)-4,9-dihidro-4,9-diokso-nafto[2,3-d]tiazols kā jauns produkts. 32. 2-(3-Bromfuran-2-il)-4,9-dihidro-4,9-diokso-nafto[2,3-d]tiazols kā jauns produkts. 33. 2-(4-Bromfuran-2-il)-4,9-dihidro-4,9-diokso-nafto[2,3-d]tiazols kā jauns produkts. 34. 4,9-Dihidro-4,9-diokso-2-(5-nitrofuran-2-il)-nafto[2,3-d]tiazols kā jauns produkts. 35. 2-(5-Aminofuran-2-il)-4,9-dihidro-4,9-diokso-nafto[2,3-d]tiazols kā jauns produkts. 4 36. 2-(5-Acetamidofuran-2-il)-4,9-dihidro-4,9-diokso-nafto[2I3-d]tiazols kā jauns produkts. 37. 4,9-Dihidro-4,9-diokso-2-(5-oksimetilfuran-2-il)-nafto[2,3-d]tiazols kā jauns produkts. 38. 2-(5-Acetoksimetilfuran-2-il)-4,9-dihidro-4,9-diokso-nafto[2,3-d]tiazols kā jauns produkts. 39. 4,9-Dihidro-4,9-diokso-2-(5-metil-2-furil)-nafto[2,3-d]tiazols kā jauns produkts. 40. 4,9-Dihidro-4,9-diokso-2-(4,5-dimetil-2-furil)-nafto[2,3-d]tiazols kā jauns produkts. 41.4,9-Dihidro-4,9-diokso-2-(5-fenil-2-oksazolil)-nafto[2,3-d]tiazols kā jauns produkts. 42. 4,9-Dihidro-4,9-diokso-2-(2-tiazolil)-nafto[2,3-d]tiazois kā jauns produkts. 43. 4,9-Dihidro-4I9-diokso-6-fluor-2-(2-furil)-nafto[2,3-d]tiazols kā jauns produkts. 44. 4,9-Dihidro-4I9-diokso-7-fluor-2-(2-furil)-nafto[2,3-d]tiazols kā jauns produkts. 45. 4,9-Dihidro-4I9-diokso-6-fluor-2-fenilnafto[2,3-d]tiazols kā jauns produkts. 46. 4,9-Dihidro-4,9-diokso-7-fluor-2-fenilnafto[2)3-d]tiazols kā jauns produkts. 47. 419-Dihidro-4,9-diokso-6-fluor-2-(5-metil-2-furil)nafto[2,3-d]tĪazols kā jauns produkts. 48. 4,9-Dihidro-4,9-diokso-7-fluor-2-(5-metil-2-furil)-nafto[2,3-d]tiazols kā jauns produkts. 5 LV 12188 49. 4,9-Dihidro-4,9-diokso-6-fluor-2-(4-fluorfenil)-nafto[2,3-d]tiazols kā jauns produkts. 50. 4,9-Dihidro-4,9-diokso-7-fluor-2-(4-fluorfenil)-nafto[2,3-d]tiazols kā jauns produkts. 51.4.9- Dihidro-4,9-diokso-6-fluor-2-(4-metilfenil)-nafto[2,3-d]tiazols kā jauns produkts. 52. 4,9-Dihidro-4,9-diokso-7-fluor-2-(4-metilfenil)-nafto[2,3-d]tiazols kā jauns produkts. 53. 4,9-Dihidro-4,9-diokso-5-fluor-2-(2-furil)-nafto[2,3-d]tiazols kā jauns produkts. 54. 4,9-Dihidro-4,9-diokso-8-fluor-2-(2-furil)-nafto[2,3-d]tiazols kā jauns produkts. 55. 6-Hlor-4,9-dihidro-4,9-diokso-2-(2-furil)-nafto[2,3-d]tiazols kā jauns produkts. 56. 7-Hlor-4,9-dihidro-4)9-diokso-2-(2-furil)-nafto[2,3-d]tiazols kā jauns produkts. 57. 4,9-Dihidro-4,9-diokso-2-(2-furil)-5-metoksinafto[2,3-d]tiazols kā jauns produkts. 58. 419-Dihidro-4>9-diokso-2-(2-furil)-8-metoksinafto[2,3-d]tiazols kā jauns produkts. 59. 4,9-Dihidro-4,9-diokso-2-(2-furil)-5-oksinafto[2,3-d]tiazols kā jauns produkts. 60. 4,9-Dihidro-4,9-diokso-2-(2-furil)-8-oksinafto[2,3-d]tiazols kā jauns produkts. 61.4.9- Dihidro-4,9-diokso-2-(2-furil)-6-metoksinafto[2.3-d]tiazols kā jauns produkts. 62. 4,9-Dihidro-4,9-diokso-2-(2-furil)-7-metoksinafto[2.3-d]tiazols kā jauns produkts. 6 63. 4,9-Dihidro-4,9-diokso-2-furil-6-metilnafto[2,3-d]tiazols kā jauns produkts. 64. 4,9-Dihidro-4,9-diokso-2-furil-7-metilnafto[2,3-d]tiazols kā jauns produkts. 65. 4,9-Dihidro-4,9-diokso-6-metil-2-fenilnafto[2,3-d]tiazols kā jauns produkts. 66. 4,9-Dihidro-4,9-diokso-7-metil-2*fenilnafto[2,3-d]tiazols kā jauns produkts. 67. 4,9-Dihidro-4>9-diokso-2-furil-5-metilnafto[2,3-d]tiazols kā jauns produkts. 68. 4,9-Dihidro-4,9-diokso-2-furil-8-metilnafto[2,3-d]tiazols kā jauns produkts. 69. 4)9-Dihidro-4,9-diokso-5-metil-2-fenilnafto[2,3-d]tiazols kā jauns produkts. 70. 4,9-Dihidro-4,9-diokso-8-metil-2-fenilnafto[2,3-d]tiazols kā jauns produkts. 71. 1,4-Dihidro-1,4-diokso-5-metoksinaftalīns kā jauns starpprodukts. 72. 2,3-Dibrom-1,4-dihidro-1,4-diokso-5-metoksinaftalīns kā jauns starpprodukts. 73. 2-Amino-3-brom-1,4-dihidro-1,4-diokso-5-metoksinaftalīns kā jauns starpprodukts. 74. 2-Amino-3-brom-1,4-dihidro-1,4-diokso-8-metoksinaftalīns kā jauns starpprodukts. 75. 2,3-Dibrom-1,4-dihidro-1,4-diokso-6-fluornaftalīns kā jauns starpprodukts. 76. 2-Amino-3-brom-l,4-dihidro-1,4-diokso-6-fluornaftalīns kā jauns starpprodukts. 77. 2-Amino-3-brom-7-fluor-1,4-dihidro-1,4-diokso-7-fIuornaftalīns kā jauns starpprodukts. 7 LV 12188 78. 2,3-Dibrom-1,4-dihidro-1,4-diokso-5-fluornaftalTns kā jauns starpprodukts. 79. 2-Amino-3-brom-5-fluor-1,4-dihidro-1,4-diokso-naftalīns kā jauns starpprodukts. 80. 2-Amino-3-brom-8-fluor-1,4-dihidro-1,4-diokso-naftalīns kā jauns starpprodukts. 81. 2-Amino-3-hlor-1,4-dihidro-1,4-diokso-6-metilnaftalīns kā jauns starpprodukts. 82. 2-Amino-3-hlor-1,4-dihidro-1,4-diokso-7-metilnaftalīns kā jauns starpprodukts. 83. 2,3-Dibrom-1,4-dihidro-1,4-diokso-5-metilnaftalīns kā jauns starpprodukts. 84. 2-Amino-3-brom-1,4-dihidro-l ,4-diokso-5-metilnaftalīns kā jauns starpprodukts. 85. 2-Amino-3-brom-1,4-dihidro-1,4-diokso-8-metilnaftalīns kā jauns starpprodukts.
  2. 86. Savienojumu saskaņā ar vienu no 1 .-70. punktiem pielietojums ārstnieciska preparāta iegūšanai, kas paredzēts funkcionālās vai organiskās venozās nepietiekamības ārstēšanai.
  3. 87. Savienojumu saskaņā ar vienu no 1 .-70. punktiem pielietojums ārstnieciska preparāta iegūšanā, kas paredzēts hemoroīdu ārstēšanai.
  4. 88. Savienojumu saskaņā ar vienu no 1.-70. punktiem pielietojums ārstnieciska preparāta iegūšanā, kas paredzēts migrēnas ārstēšanai.
  5. 89. Savienojumu saskaņā ar vienu no 1.-70. punktiem pielietojums ārstnieciska preparāta iegūšanā, kas paredzēts dermatoloģijas un sirds asinsvadu un kaulu-locītavu iekaisumu ārstēšanai. 8
  6. 90. Savienojumu saskaņā ar vienu no 1 .-70. punktiem pielietojums ārstnieciska preparāta iegūšanā, kas paredzēts šoka stāvokļa, kas saistīts ar arteriāla spiediena lielu kritumu, it īpaši septiska šoka stāvokļa ārstēšanai.
LVP-98-136A 1995-12-12 1998-06-12 1,4-dihidro-1,4-diokso-1h-naftalīna triciklisku atvasinājumu pielietojums jaunu savienojumu iegūšanai un to izmantošana terapijā LV12188B (lv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9514683A FR2742153B1 (fr) 1995-12-12 1995-12-12 Utilisation de derives tricycliques du 1,4-dihydro-1,4- dioxo-1h-naphtalene, nouveaux composes obtenus et leur application en therapeutique
PCT/FR1996/001973 WO1997021684A1 (fr) 1995-12-12 1996-12-10 Utilisation de derives tricycliques du 1,4-dihydro-1,4-dioxo-1h-naphtalene, nouveaux composes obtenus et leur application en therapeutique

Publications (2)

Publication Number Publication Date
LV12188A LV12188A (lv) 1998-12-20
LV12188B true LV12188B (lv) 1999-07-20

Family

ID=9485393

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-98-136A LV12188B (lv) 1995-12-12 1998-06-12 1,4-dihidro-1,4-diokso-1h-naftalīna triciklisku atvasinājumu pielietojums jaunu savienojumu iegūšanai un to izmantošana terapijā

Country Status (26)

Country Link
US (1) US6262095B1 (lv)
EP (1) EP0876356B1 (lv)
JP (1) JP2000501724A (lv)
KR (1) KR19990072080A (lv)
AP (1) AP889A (lv)
AR (1) AR005054A1 (lv)
AT (1) ATE207907T1 (lv)
AU (1) AU716199B2 (lv)
BR (1) BR9611935A (lv)
CA (1) CA2240279A1 (lv)
CZ (1) CZ181198A3 (lv)
DE (1) DE69616598D1 (lv)
EE (1) EE9800174A (lv)
FR (1) FR2742153B1 (lv)
HU (1) HUP9901247A3 (lv)
ID (1) ID16081A (lv)
IL (1) IL124558A0 (lv)
LT (1) LT4491B (lv)
LV (1) LV12188B (lv)
NO (1) NO982696L (lv)
NZ (1) NZ323967A (lv)
OA (1) OA10696A (lv)
PL (1) PL327168A1 (lv)
RU (1) RU2178791C2 (lv)
TR (1) TR199801069T2 (lv)
WO (1) WO1997021684A1 (lv)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003999A (en) * 1997-12-19 1999-07-12 Advanced Research And Technology Institute, Inc. Modulators of ryanodine receptors comprising 2-(aryl)-4,7-dioxobenzothiazoles and analogues thereof
CA2433018A1 (en) * 2000-12-21 2002-06-27 Joel C. Barrish Thiazolyl inhibitors of tec family tyrosine kinases
AR061478A1 (es) 2006-06-19 2008-08-27 Takeda Pharmaceutical Compuesto triciclico y composicion farmaceutica
US7754463B2 (en) 2006-06-20 2010-07-13 Dana-Farber Cancer Institute Inhibitors of USP1 Deubiquitinating Enzyme Complex
CA2797719C (en) 2010-04-30 2019-11-26 Dana-Farber Cancer Institute, Inc. Small molecule inhibitors of usp1 deubiquitinating enzyme activity
US9040713B2 (en) * 2010-09-27 2015-05-26 Emory University Methods of managing blood sugar levels and compositions related thereto
US9725425B1 (en) 2014-02-25 2017-08-08 Dana-Farber Cancer Institute, Inc. Compounds and methods for treating cancer
RU2545091C1 (ru) * 2014-03-18 2015-03-27 Федеральное государственное бюджетное учреждение "Российский онкологический научный центр имени Н.Н. Блохина" Российской академии медицинских наук (ФГБУ "РОНЦ им. Н.Н. Блохина" РАМН) 1-R-4,9-ДИОКСО-1H-НАФТО[2,3-d][1,2,3]ТРИАЗОЛ-4-ОКСИМ-2-ОКСИДЫ И ИХ ПРОИЗВОДНЫЕ, ОБЛАДАЮЩИЕ ЦИТОТОКСИЧЕСКОЙ АКТИВНОСТЬЮ
US10829427B2 (en) 2015-12-18 2020-11-10 The Board Of Regents Of The University Of Texas System Naphthoquinones, pro-drugs, and methods of use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3039925A (en) 1957-04-24 1962-06-19 Bayer Ag Compositions for the treatment of tuberculosis
US4746676A (en) 1984-09-12 1988-05-24 Rorer Pharmaceutical Corporation Carboxyalkyl dipeptide compounds
JPH05112533A (ja) * 1991-05-08 1993-05-07 Upjohn Co:The イミダゾベンゾキノン類およびこれを有効成分とする高血圧・鬱血性心不全の予防・治療剤

Also Published As

Publication number Publication date
EE9800174A (et) 1998-12-15
TR199801069T2 (xx) 1998-08-21
IL124558A0 (en) 1998-12-06
ATE207907T1 (de) 2001-11-15
AR005054A1 (es) 1999-04-07
AU1101897A (en) 1997-07-03
PL327168A1 (en) 1998-11-23
JP2000501724A (ja) 2000-02-15
BR9611935A (pt) 1999-05-18
DE69616598D1 (de) 2001-12-06
EP0876356B1 (fr) 2001-10-31
CZ181198A3 (cs) 1998-09-16
NO982696L (no) 1998-08-11
NO982696D0 (no) 1998-06-11
HUP9901247A3 (en) 2000-08-28
LV12188A (lv) 1998-12-20
HUP9901247A2 (hu) 1999-08-30
AU716199B2 (en) 2000-02-24
RU2178791C2 (ru) 2002-01-27
WO1997021684A1 (fr) 1997-06-19
KR19990072080A (ko) 1999-09-27
LT4491B (lt) 1999-04-26
AP9801275A0 (en) 1998-06-30
OA10696A (fr) 2002-11-26
US6262095B1 (en) 2001-07-17
CA2240279A1 (fr) 1997-06-19
LT98085A (en) 1998-11-25
ID16081A (id) 1997-09-04
FR2742153B1 (fr) 1998-02-13
NZ323967A (en) 2000-06-23
AP889A (en) 2000-11-17
EP0876356A1 (fr) 1998-11-11
FR2742153A1 (fr) 1997-06-13

Similar Documents

Publication Publication Date Title
CN104327084B (zh) Bcr‑abl的小分子豆蔻酸酯抑制剂及其使用方法
DE69930120T2 (de) Annellierte azepinone als inhibitoren cyclin-abhängiger kinasen
JPS61218589A (ja) ５―（６―イミダゾ〔１，２―ａ〕ピリジニル）ピリジン誘導体
JP2001504109A (ja) ベンゾ複素環ジスタマイシン誘導体、それらを製造する方法および抗腫瘍および抗ウイルス剤としてのそれらの用途
Venkatesh et al. Design and synthesis of Quinazolinone, Benzothiazole derivatives bearing guanidinopropanoic acid moiety and their Schiff bases as cytotoxic and antimicrobial agents
LV12188B (lv) 1,4-dihidro-1,4-diokso-1h-naftalīna triciklisku atvasinājumu pielietojums jaunu savienojumu iegūšanai un to izmantošana terapijā
WO2018214639A1 (zh) 2-氮杂环-5-三氟甲基-8-硝基苯并(硫代)吡喃-4-酮类化合物及其制备方法和用途
CA2557942C (fr) Derives de carbamate de 2h- ou 3h-benzo[e]indazol-1-yle, leur preparation et leur application en therapeutique
CA2513059A1 (fr) Nouveaux derives d'azepines tricycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP2000502081A (ja) １，４―ジヒドロ―１，４―ジオキソナフタレンのヘテロ芳香族及び三環式誘導体の利用、得られる新規化合物並びにその治療用途
KR100755579B1 (ko) 단백질 티로신 포스파타제 억제제로서디아미노피롤로퀴나졸린 화합물
CA2481460C (en) 3-heteroaryl-3,5-dihydro-4-oxo-4h-pyridazino[4,5-b]indole-1-acetamide derivatives, their preparation and their application in therapeutics
US5981544A (en) Mono-- or diketone tetracyclic derivatives and therapeutical uses thereof
JP2013505922A (ja) 新規アミノ酸誘導体、その製造法、及びｍｅｔファミリーによる発癌性シグナルの阻害剤としてのその治療的使用
MXPA98004717A (es) Utilizacion de derivados triciclicos de 1,4-dihidro-1,4-dioxo-1h-naftaleno, nuevos compuestos obtenidos y su aplicacion terapeutica
KR20240110273A (ko) 새로운 인돌리진-피롤로피리미딘 하이브리드 유도체 제조방법 및 이를 포함하는 항암제 조성물
DE19947297A1 (de) Cyclische Biphenyle, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel
JP2009256274A (ja) ５員複素環化合物を有効成分とする抗ガン剤および新規５員複素環化合物
DE4311782A1 (de) Indazol-Derivate und diese enthaltende Arzneimittel
MXPA06009859A (en) 2h or 3h-benzo[e]indazol-1-yle carbamate derivatives, the preparation and therapeutic use thereof